News Hub | News Direct

Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
Article thumbnail News Release

US radiologists working with Nutex Health Hospitals now have access to world-class DrAid™, an artificial intelligence doctor’s assistant

Vingroup

HANOI, VIETNAM - Media OutReach - 3 July 2023 - VinBrain's advanced AI assistant in diagnostic imaging, DrAid™ Chest XR, was successfully integrated into the radiology workflow of Nutex Health Inc. in Houston, Texas, United States through a Software Subscription License Agreement – SaaS (Software as a Service) model. Nutex Health Inc. is a physician-led healthcare organization with 19 hospitals across 8 states, focusing on functional emergency care and primary care. With a revenue of USD219.2 million in the fiscal year 2022, Nutex Health Inc. has recognized the positive impact of DrAid™ during its 90-day trial, particularly in the ER department's radiology care pathway (Emergency Radiology). DrAid™ CXR employs AI algorithms to prioritize and triage abnormalities in chest X-rays with an impressive accuracy rate of 91%. Integrating DrAid™ Chest XR into Nutex Health facilities allows for the timely identification and prioritization of time-sensitive findings in chest X-rays. Furthermore, it assists in clinical management and reduces the chances of errors or delays in reporting. Within a year of receiving the first FDA 510(k) clearance last September, DrAid TM successfully secured commercialization in the United States for its AI-enabled Radiology v1. This rapid achievement highlights the efficiency and effectiveness of the system in detecting suggestive pneumothorax findings in human chest X-rays. Dr. Tom Vo, CEO & Chairman of Nutex Health Inc., commended DrAid™ CXR for its remarkable impact, stating, " The software is a high-standard product capable of identifying abnormalities in chest X-rays." By this, DrAid™ CXR enhances the probability of confirming a case and saves valuable time for doctors, especially during odd or late-night hours in time-sensitive settings like the ER departments. Dr. Vo concluded, " We selected a great AI company to optimize the service workflows of our ER hospitals. " Mr. Steven Truong, VinBrain’s Chief Executive Officer, expressed his thoughts on this deployment: “This collaboration represents the integration of innovative medical infrastructure in micro-hospitals, aligning with the global healthcare industry's ongoing transformation towards AI-powered solutions”. VinBrain persists in challenging markets like the US while developing new AI products to combat global diseases. In June, their DrAid™ Liver Cancer CT gained recognition at the esteemed 4th Stanford AIMI Symposium (USA) and the 10th Radiological Congress of Ho Chi Minh City, Vietnam. Liver cancer accounted for 905,677 new cases and 830,180 deaths in 2020, with a projected risk for over 90 countries and 30 million lives by 2040. VinBrain remains committed to addressing this pressing global health issue. VinBrain's innovative platform employs advanced AI technology for rapid and accurate identification of abnormal liver lesions. It not only facilitates the detection of cancerous growths but also delivers precise quantitative measurements of lesion volume and diameter, even for tumors as small as 5mm. At the 10th Radiological Congress of Ho Chi Minh City, Nguyen Minh Duc, MD, Ph.D., Head of the Scientific Committee at Pham Ngoc Thach University of Medicine in Vietnam, and Deputy Editor of Radiology Case Reports, commended “This exceptional medical imaging innovation developed by skilled Vietnamese professionals highlights VinBrain's proficiency in the AI era. The technology holds promise for assisting oncologists in assessing liver cancer and has the potential to expand its application to other types of cancer.” During his recent visit to VinBrain's office in Hanoi, Vietnam, Gregory Moore, MD, Ph.D., Corporate Vice President of Microsoft Health and Adjunct Clinical Professor of Radiology at Stanford University School of Medicine, who holds a Radiological Sciences Ph.D. from MIT and specializes in Neuroradiology, expressed his admiration for VinBrain. He remarked, "I am inspired by how VinBrain has swiftly responded to the pressing needs by overcoming obstacles, embracing cutting-edge technology, and delivering a positive impact to the healthcare ecosystem in Vietnam, Southeast Asia, and now, with their first FDA approval, in the United States." He further described VinBrain as a trailblazing health tech company that generates contagious momentum. Nutex Health Inc. Nutex Health Inc. (NASDAQ: NUTX) is a US-based for-profit healthcare delivery system headquartered in Houston, Texas. The company operates in two divisions: The Hospital Division and the Population Health Management Division. Currently, the Hospital Division owns and operates 19 facilities across eight states, and there are plans for an additional 14 facilities shortly. VinBrain VinBrain is a startup that has been operating for four years and is backed by Vingroup, the largest conglomerate in Vietnam. The company aims to integrate AI and IoT technologies to enhance people's lives and productivity. With an impressive portfolio of cutting-edge tech products and platforms, such as DrAid™ and AIScaler™, VinBrain has developed more than 300 AI models specifically designed for processing medical images. These models have been built using a dataset that comprises over 2.5 million images and extensive text-based big data from Vietnam, the USA, and India. One of VinBrain's notable achievements is the deployment of DrAid™, a comprehensive AI platform for diagnostic radiology, in over 100 hospitals across Vietnam, Myanmar, New Zealand, and the USA. Contact Details VinBrain Hang Vu, Chief Marketing Officer +84 90 393 12 46 hang.vu@vinbrain.net Company Website https://draid.ai

July 03, 2023 09:30 AM Eastern Daylight Time

Image
Article thumbnail News Release

Creo Medical Group "looking very well" - Proactive Research Analyst

Creo Medical Group PLC

Proactive Research Analyst Daniel Appiah gives the highlights from his latest research note on UK-based medical device company Creo Medical Group PLC (AIM:CREO). Creo recently announced that the medical device company's Speedboat Inject product was used for the first time in an upper gastrointestinal (GI) procedure in Europe, a major milestone for the business. Appiah says Creo is "looking very well" and gives his take on what recent developments are likely to mean for the company's financials. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

July 03, 2023 09:09 AM Eastern Daylight Time

Video
Article thumbnail News Release

Prenetics Global signs "transformational" $200mln deal to create cancer screening JV

Prenetics Global Ltd

Prenetics Global Ltd (NASDAQ:PRE) CEO Danny Yeung speaks to Thomas Warner from Proactive after announcing a $200mln deal to create a multi-cancer early detection screening joint venture with Professor Dennis Lo. The new JV will be called Insighta and Yeung will serve as its first CEO. Yeung reveals plans to launch tests targeting lung and liver cancer in 2025, with a goal of selling over 30 million tests annually by 2030. Contact Details Proactive United States Proactive United States +1 347-449-0879 action@proactiveinvestors.com

June 30, 2023 08:00 AM Eastern Daylight Time

Video
Article thumbnail News Release

Xeris Biopharma CEO reveals impact of CSO's departure and exciting future plans

Xeris Biopharma Holdings

Xeris Biopharma CEO Paul Edick joined Proactive's Natalie Stoberman to share the resignation of the company's Chief Scientific Officer and Founder Dr. Steven Prestrelski as he transitions to a consulting role with Xeris. Edick said the impact of Dr. Prestrelski stepping down as the CSO will be negligible as Xeris Biopharma has transitioned from a research and development company to primarily a commercial business with development activities. Edick adds that Xeris Biopharma will retain Dr. Prestrelski as a consultant for the next year or two as needed. Edick also expressed excitement for Dr. Prestrelski's future endeavours, potentially starting another company focused on peptides and research which aligns more with his interests, and emphasized that the rest of the company is operating well with a healthy business, three growing products, partnerships with Big Pharma, and another product in the pipeline. Contact Details Proactive Investors +1 347-449-0879 na-editorial@proactiveinvestors.com

June 29, 2023 04:19 PM Eastern Daylight Time

Video
Article thumbnail News Release

NanoViricides take big step forward beginning trials on its antiviral drug NV-CoV-2

NanoViricides

NanoViricides CEO Dr Anil Diwan joined Steve Darling from Proactive to share news about the beginning of clinical trials for its broad-spectrum antiviral drug NV-CoV-2. This is with two oral drug products NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies. Diwan told Proactive the Phase 1a/1b safety and efficacy clinical trial began June 17th and is aimed at satisfying the as-yet-unmet medical need for a highly effective broad-spectrum, pan-coronavirus drug that can be used for all patient populations. The trial will use patients with mild to moderate COVID-19 to assess indication of efficacy. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

June 29, 2023 03:00 PM Eastern Daylight Time

Video
Article thumbnail News Release

RenovoRx encountering "a lot of enthusiasm" for innovative cancer platform

RenovoRx Inc

RenovoRx Inc (NASDAQ:RNXT) CEO Shaun Bagai speaks to Thomas Warner during a visit to Europe to present at the ESMO World Congress on Gastrointestinal Cancer (ESMO GI) in Barcelona. Bagai gives an overview of the lead candidate product RenovoGem that he has presented to the Congress, before going on to explain where the product is in its development cycle. He says the product has met with "a lot of enthusiasm" so far and reveals his hopes of getting early approval from the FDA "next year or early in 2025." Contact Details Proactive United States Proactive United States +1 347-449-0879 action@proactiveinvestors.com

June 29, 2023 11:42 AM Eastern Daylight Time

Video
Article thumbnail News Release

Poolbeg Pharma and CytoReason identify "very exciting influenza targets"

Poolbeg Pharma PLC

Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) CEO Jeremy Skillington and CytoReason co-founder and CEO David Harel speak to Thomas Warner from Proactive after announcing what they call a "significant breakthrough" in their world-first influenza Artificial Intelligence ('AI') Programme. Skillington says that the collaboration has yielded some "very exciting influenza targets" and that Poolbeg will now be "actively exploring the most effective way to bring them forward into development." He also highlights Poolbeg's RSV-focused AI collaboration with CytoReason that concluded in 2022, saying that Poolbeg "is now working on validating those targets... and will have data before the end of the year." Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

June 29, 2023 03:54 AM Eastern Daylight Time

Video
Article thumbnail News Release

TransCode Therapeutics making preclinical progress with lead metastatic cancer candidate

TransCode Therapeutics Inc

TransCode Therapeutics CEO Michael Dudley joined Proactive's Natalie Stoberman to share the latest progress from its lead RNA oncology candidate TTX-MC138. TransCode is an RNA oncology company created on the belief that cancer can be more effectively treated using RNA therapeutics. The company has created a platform of drug candidates designed to target a variety of tumour types with the objective of significantly improving patient outcomes. TransCode's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which is believed to cause approximately 90% of all cancer deaths totalling over nine million per year worldwide. Contact Details Proactive USA +1 347-449-0879 na-editorial@proactiveinvestors.com

June 28, 2023 03:49 PM Eastern Daylight Time

Video
Article thumbnail News Release

Tonix Pharmaceuticals fibromyalgia study published in American College of Rheumatology

Tonix Pharmaceuticals

Tonix Pharmaceuticals CEO Seth Lederman joined Proactive's Natalie Stoberman to discuss the recent publication of the company's Phase 3 study on TNX-102 SL for fibromyalgia management in the American College of Rheumatology. Lederman said the article outlined how the study's results showed improvements in widespread pain and fatigue, which are significant symptoms of fibromyalgia. He explains that TNX-102 SL, a sublingual tablet taken at bedtime, targets sleep quality to enhance overall fibromyalgia symptoms. With the upcoming confirmatory Phase 3 trial results, Lederman said Tonix aims to file a new drug application for TNX-102 SL. Contact Details Proactive Studio +1 347-449-0879 na-editorial@proactiveinvestors.com

June 28, 2023 03:21 PM Eastern Daylight Time

Video
1 ... 9293949596 ... 250